Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesSafety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas
International Journal of Radiation Oncology*Biology*Physics, 09/02/09
Gutin PH et al. – Bevacizumab with HFSRT is safe and well tolerated. Radiographic responses, duration of disease control, and survival suggest that this regimen is active in recurrent malignant glioma.
Related Articles
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors
Journal of Clinical Oncology, 11/19/09
Relevance Score: 92%
Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies
Journal of Cancer Research & Clinical Oncology, 11/17/09
Relevance Score: 91%
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
Relevance Score: 91%
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
Journal of Clinical Oncology, 10/22/09
Relevance Score: 89%
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501
Journal of Clinical Oncology, 10/15/09
Relevance Score: 89%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A heritable predisposition to pituitary tumors
Pituitary, 12/18/09
Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor
Pituitary, 12/18/09
Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique
Neurosurgical Focus, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor